Naltrexone/bupropion for binge‐eating disorder: A randomized, double‐blind, placebo‐controlled trial
Obesity · 2023
DOI: 10.1002/oby.23898 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Obesity, 2023. Verfasst von Carlos M Grilo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, USA. Hauptthemen laut MEDLINE: Binge-Eating Disorder, Bulimia. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NCATS NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.
Abstract (Originalsprache)
Objective
Binge‐eating disorder (BED) is a prevalent psychiatric disorder associated with obesity. Few evidence‐based treatments exist for BED, particularly pharmacological options. This study tested the efficacy of naltrexone/bupropion for BED.
Methods
A randomized, double‐blind, placebo‐controlled, 12‐week trial tested naltrexone/bupropion for BED with and without obesity. Eighty‐nine patients (70.8% women, 69.7% White, mean age 45.7 y, mean BMI 35.1 kg/m 2 , 77.5% with BMI ≥ 30 kg/m 2 ) were randomized to placebo ( n = 46) or naltrexone/bupropion ( n = 43), with randomization stratified by obesity status and gender; 92.1% completed post‐treatment assessments.
Results
Mixed models of binge‐eating frequency revealed significant reductions that did not differ significantly between naltrexone/bupropion and placebo. Logistic regression of binge‐eating remission rates revealed that naltrexone/bupropion and placebo did not differ significantly. Obesity status did not predict, or moderate, binge‐eating outcomes considered either continuously or categorically. Mixed models revealed that naltrexone/bupropion was associated with significantly greater percentage weight loss than placebo. Logistic regression revealed that naltrexone/bupropion had significantly higher rates of attaining ≥5% weight loss than placebo (27.9% vs. 6.5%). Obesity status did not predict or moderate weight‐loss outcomes.
Conclusions
Naltrexone/bupropion did not demonstrate effectiveness for reducing binge eating relative to placebo but showed effectiveness for weight reduction in patients with BED. Obesity status did not predict or moderate medication outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, USA.
- Department of Medicine (Endocrinology and Metabolism), Yale University School of Medicine, New Haven, Connecticut, USA.
ORCID-Profile: Carlos M Grilo, Janet A Lydecker, Ania M Jastreboff
Förderung
- NIDDK NIH HHS
- NCATS NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Grilo, C. M., Lydecker, J. A., Jastreboff, A. M., Pittman, B., & McKee, S. A. (2023). Naltrexone/bupropion for binge‐eating disorder: A randomized, double‐blind, placebo‐controlled trial. Obesity. https://doi.org/10.1002/oby.23898
Vancouver
Grilo CM, Lydecker JA, Jastreboff AM, Pittman B, McKee SA. Naltrexone/bupropion for binge‐eating disorder: A randomized, double‐blind, placebo‐controlled trial. Obesity. 2023. doi:10.1002/oby.23898
BibTeX
@article{Grilo2023,
author = {Grilo, Carlos M and Lydecker, Janet A and Jastreboff, Ania M and Pittman, Brian and McKee, Sherry A},
title = {Naltrexone/bupropion for binge‐eating disorder: A randomized, double‐blind, placebo‐controlled trial},
journal = {Obesity},
year = {2023},
doi = {10.1002/oby.23898}
}
EUVIMED